Skip to main content
SpringerLink
Log in
Book cover

Principles of Cancer Biotherapy pp 284–317Cite as

Antibody Therapy

  • Chapter

Abstract

The potential of antibody-mediated anticancer therapy has been recognized since the turn of the century when Paul Ehrlich espoused the ‘magic bullet’ concept [64]. The rationale for this approach is derived from immunological principles which were first recognized in the study of microbiology. Foreign cells, when injected into an animal, induce an immune response characterized by the production of immunoglobulin proteins, called antibodies, each of which binds specifically to certain collections of cell surface molecules, termed antigens. Chemically such antigens are characterized as glycoproteins, glycolipids, polysaccharides, etc. An antigen found only on cancer cells would be a tumor-specific antigen, while one present on some normal tissues, but more prevalent on cancer cells, would be called a tumorassociated antigen (TAA).

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adair JR. Engineering antibodies for therapy. Immunol Rev 1992; 130: 5–40.

    Article  PubMed  CAS  Google Scholar 

  2. Avner BP, Liao SK, Avner B, et al. Therapeutic murine monoclonal antibodies developed for individual cancer patients. J Biol Response Modif 1989; 8: 25–36.

    CAS  Google Scholar 

  3. Badger CC, Bernstein ID. Therapy of murine leukemia with monoclonal antibody against a normal/differentiation antigen. J Exp Med 1983; 157: 828–842.

    Article  PubMed  CAS  Google Scholar 

  4. Bajorin DF, Chapman PB, Wong G, et al. Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma. Cancer Res 1990; 50: 7490–7495.

    PubMed  CAS  Google Scholar 

  5. Ball ED, Bernier GM, Cornwell III GG, et al. Monoclonal antibodies to myeloid differentiation antigens: In vivo studies of three patients with acute myelogenous leukemia. Blood 1983; 62: 1203–1210.

    PubMed  CAS  Google Scholar 

  6. Ball ED, Selvaggi K, Hurd D, et al. A phase I clinical trial of serotherapy in patients with acute myeloid leukemia with an IgM monoclonal antibody to CD15. J Clin Oncol [in press]

    Google Scholar 

  7. Barker E, Mueller BM, Handgretinger R, et al. Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res 1991; 51: 144–149.

    PubMed  CAS  Google Scholar 

  8. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of recombinant human anti-Her2 monoclonal antibody (rhuMab Her2) in stage IV breast cancer; Her2 shedding dependent pharmacokinetics and antitumor activity. Proc Am Soc Clin Oncol 1990; 14: 103.

    Google Scholar 

  9. Beatty JD, Duda RB, Williams LE, et al. Preoperative imaging of colorectal carcinoma with 111-In-labeled anticarcinoembryonic antigen monoclonal antibody. Cancer Res 1986; 46: 6494–6502.

    PubMed  CAS  Google Scholar 

  10. Berinstein NL, Tang SC, Hewitt K. Objective clinical responses in patients with progressive/recurrent low grade lymphoma treated with Campath 11+ monoclonal antibody. Blood 84 Suppl 1 1994; 638a.

    Google Scholar 

  11. Bernstein ID, Tam MR, Nowinski RC. Mouse leukemia therapy with monoclonal antibodies against a thymus differentiation antigen. Science 1980: 207: 68–71.

    Article  PubMed  CAS  Google Scholar 

  12. Bernstein ID, Nowinski RC, Tam MR, et al. Monoclonal antibody therapy of mouse leukemia. In: Monoclonal Antibodies. Kennett RH, Bechtol TJ, eds. New York: Plenum Press, 1980:275–291.

    Google Scholar 

  13. Bernstein ID, Nowinski RC. Monoclonal antibody treatment of transplanted and spontaneous murine leukemia. In: Hybridomas in Cancer Diagnosis and Treatment. Mitchell MS, Oettgen HF, eds. New York: Raven Press, 1982:97–112.

    Google Scholar 

  14. Bertoli LF, Kubagawa H, Mayumi M, et al. Immunotherapy of advanced B cell malignancies with mouse monoclonal antibodies. Fed Proc 1984; 43: 1972.

    Google Scholar 

  15. Bertram JH, Gill PS, Levine AM, et al. Monoclonal antibody T101 in T-cell malignancies: a clinical, pharmo kinetic and immunologic correlation. Blood 1986; 68: 752–761.

    PubMed  CAS  Google Scholar 

  16. Billing R, Chatterjee S. Prolongation of skin allograft survival in monkeys treated with anti-la and anti-blast/ monocyte monoclonal antibodies. Transplant Proc 1983; 15:649–650.

    Google Scholar 

  17. Borup-Christensen P, Erb K, Jensenius JC, et al. Humanhuman hybridomas for the study of antitumor immune response in patients with colorectal cancer. Int J Cancer 1986;37:683–688.

    Article  PubMed  CAS  Google Scholar 

  18. Brittingham TE, Chaplin H. Production of a human antileukemic leukocyte serum and its therapeutic trial. Cancer 1960; 1:412–418.

    Article  Google Scholar 

  19. Brown BA, Davis GL, Saltzgaber-Muller J, et al. Tumor specific genetically engineered murine/human chimeric monoclonal antibody. Cancer Res 1987; 47: 3577–3583.

    PubMed  CAS  Google Scholar 

  20. Brown SL, Miller RA, Horning SJ, et al. Treatment of Bcell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon. Blood 1989; 73: 651–661.

    PubMed  CAS  Google Scholar 

  21. Brown SL, Miller RA, Levy R. Antiidiotype antibody therapy of B-cell lymphoma. Semin Oncol 1989; 16: 199–210.

    PubMed  CAS  Google Scholar 

  22. Brown PN, Geisler CH, Nissen NI. Treatment with CAMPATH-1H antibody in patients with relapsed non- Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 1994; 84(suppl 1): 653a.

    Google Scholar 

  23. Buchler M, Friess H, Schultheiss K-H, et al. A randomized controlled trial of adjuvant immunotherapy (murine monoclonal antibody 494/32) in resectable pancreatic cancer. Cancer 1991; 68: 1507–1512.

    Article  PubMed  CAS  Google Scholar 

  24. Buter J, Janssen RAJ, Martens A, et al. Phase I/II study of low-dose intravenous OKT3 and subcutaneous interleukin- 2 in metastatic cancer. Eur J Cancer 1993; 29A: 2108–2113.

    Article  PubMed  CAS  Google Scholar 

  25. Burdette S, Schwartz RS. Current concepts: Immunology. Idiotypes and idiotypic network. N Engl J Med 1987; 317: 219–224.

    Article  PubMed  CAS  Google Scholar 

  26. Burnett KG, Masuho Y, Hernandez R et al. Human monoclonal antibodies to breast cancer cells. In: Monoclonal Antibodies, Diagnostic and Therapeutic Use in Tumor and Transplantation. Chatterjee SN, ed. PSG Publishing Co., Inc., Littleton, Mass. 1985, pp 47–62.

    Google Scholar 

  27. Capone PM, Papsidero LD, Croghan GA, Chu TM. Experimental tumoricidal effects of monoclonal antibody against solid breast tumors. Proc Natl Acad Sci USA 1983; 80: 7328–7332.

    Article  PubMed  CAS  Google Scholar 

  28. Carrasquillo JA, Bunn PA, Keenan AM, et al. Radioimmunodetection of cutaneous T-cell lymphoma with 111-In-T101 monoclonal antibody. N Engl J Med 1986; 315:673–680.

    Article  PubMed  CAS  Google Scholar 

  29. Carter P, Presta L, Gorman C, et al. Humanization of an anti-pl85Her2 antibody for human cancer. Proc Natl Acad Sci 1992; 89:4285–4289.

    Article  PubMed  CAS  Google Scholar 

  30. Carter PW. Monoclonal antibodies and the biological approach to cancer. J Biol Response Modif 1985; 4: 325–339.

    CAS  Google Scholar 

  31. Casali P, Inghirami G, Nakamura R, et al. Human monoclonals from antigen-specific selection of B-lymphocytes and transformation by EBV Science 1986; 234:476–478.

    Article  PubMed  CAS  Google Scholar 

  32. Caulfield MJ, Barna B, Murthy S, et al. Phase Ia/Ib trial of an anti-GD3 monoclonal antibody (R24) in combination with interferon alpha (rHuIFNa-2a) in patients with malignant melanoma. J Biol Response Mod 1990; 9: 319–328.

    PubMed  CAS  Google Scholar 

  33. Caulfield MJ, Murthy S, Tubbs RR, et al. Treatment of chronic lymphocytic leukemia with an anti-idiotypic monoclonal antibody. Cleve Clin J Med 1989; 56: 182–188.

    PubMed  CAS  Google Scholar 

  34. Chachoua A, Oratz R. Liebes L, et al. Phase lb trial of granulocyte-macrophage colony-stimulating factor combined with murine monoclonal antibody R24 in patients with metastatic melanoma. J Immunother 1994; 16: 132–141.

    Article  CAS  Google Scholar 

  35. Cheresh DA, Honsila CJ, Staffileno LK, et al. Disialoganglioside GD3 on human melanoma serves as a relevant target antigen for monoclonal antibody-mediated tumor cytolysis. Proc Natl Acad Sci USA 1985; 82: 5155–5159.

    Article  PubMed  CAS  Google Scholar 

  36. Cheung NK V, Lazarus H, Miraldi FD, et al. Ganglioside GD2 specific monoclonal antibody 3F8: A phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 1987; 5: 1430–1440.

    PubMed  CAS  Google Scholar 

  37. Chiorazzi N, Wasserman RL, Kunkel HG. Use of Epstein- Barr virus-transformed B-cell lines for the generation of immunoglobulin-producing human B-cell hybridomas. J Exp Med 1982; 156:930–935.

    Article  PubMed  CAS  Google Scholar 

  38. Cleary ML, Meeker TC, Levy S, et al. Clustering of extensive somatic mutations in the variable region of an immunoglobulin heavy chain gene from a human B cell lymphoma. Cell 1986; 44: 97–106.

    Article  PubMed  CAS  Google Scholar 

  39. Cole SP, Campling BG, Louwman IH, Kozbor D, Roder JC. A strategy for the production of human monoclonal antibodies reactive with lung tumor cells. Cancer Res 1984; 44:2750–2753.

    PubMed  CAS  Google Scholar 

  40. Cote RJ, Morrissey DM, Houghton AN, et al. Generation of human monoclonal antibodies reactive with cellular antigens. Proc Natl Acad Sci 1983; 80: 2026–2030.

    Article  PubMed  CAS  Google Scholar 

  41. Courtenay-Luck NS, Epenetos AA, Moore R, et al. Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms. Cancer Res 1986; 46: 6489–6493.

    PubMed  CAS  Google Scholar 

  42. Creekmore S, Urba W, Kopp W, et al. Phase IB/II trial of R24 antibody and interleukin-2 in melanoma. Proc Am Soc Clin Oncol 1992; 11:345.

    Google Scholar 

  43. Currie GA. Eighty years of immunotherapy: a review of immunobiological methods used in the treatment of cancer. Int J Cancer 1972; 26: 141–153.

    CAS  Google Scholar 

  44. DePinho RA, Feldman LB, Scharff MD. Tailor-made monoclonal antibodies. Ann Intern Med 1986; 104: 225–233.

    Google Scholar 

  45. Diamond BA, Yelton DE, Scharff MD. Monoclonal antibodies: a new technology for producing serologic reagents. N Engl J Med 1981; 304: 1344–1349.

    Article  PubMed  CAS  Google Scholar 

  46. Dillman RO, Shawler DL, Sobol RE, et al. Murine monoclonal antibody therapy in two patients with chronic lymphocytic leukemia. Blood 1982; 59: 1036–1045.

    PubMed  CAS  Google Scholar 

  47. Dillman RO, Beauregard JC, Sobol RE, et al. Lack of radioimmunodetection and complications associated with monoclonal antibody cross-reactivity with an antigen on circulating cells. Cancer Res 1984; 44: 2213–2217.

    PubMed  CAS  Google Scholar 

  48. Dillman RO. Monoclonal antibodies in the treatment of cancer. CRC CritRev Hematol/Oncol 1984; 1: 357–386.

    Article  CAS  Google Scholar 

  49. Dillman RO, Shawler DL, Dillman JB, et al. Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. J Clin Oncol 1984;2:881–891.

    PubMed  CAS  Google Scholar 

  50. Dillman RO, Beauregard J, Shawler DL, et al. Clinical trial of 24 hour infusions of T101 murine monoclonal antibody. In: Reisfeld RA, Sell S, eds. Monoclonal antibodies and cancer therapy, UCLA symposia on molecular and cellular biology, new series Alan R. Liss, Inc, New York, NY 1985; 27: 133–146.

    Google Scholar 

  51. Dillman RO, Dillman JB, Halpern SE, et al. Toxicities and side effects associated with intravenous infusions of monoclonal antibodies. J Biol Response Modif 1986; 5: 73–84.

    CAS  Google Scholar 

  52. Dillman RO, Beauregard J, Shawler DL, et al. Continuous infusion ofTlOl monoclonal antibody in chronic lymphocytic leukemia and cutaneous T-cell lymphoma. J Biol Response Mod 1986; 5: 394–410.

    PubMed  CAS  Google Scholar 

  53. Dillman RO, Johnson DE, Shawler DL. Immune interferon modulation of in vitro murine anti-human T-cell monoclonal antibody mediated cytotoxicity. J Immunol 1986; 136: 728–731.

    PubMed  CAS  Google Scholar 

  54. Dillman RO, Beauregard J, Ryan KP, et al. Radioimmunodetection of cancer using indium-labeled monoclonal antibodies. International symposium on labeled and unlabeled antibodies in cancer diagnosis and therapy. NCI Monographs 1987; 3: 33–36.

    PubMed  Google Scholar 

  55. Dillman RO. The human antimouse and antiglobulin responses to monoclonal antibodies. Antibody, Immunocon & Radiopharm 1990; 3:1–15.

    Google Scholar 

  56. Dillman RO, Shawler DL, McCallister TJ, Halpern SE. Human anti-mouse antibody response in cancer patients following single low-dose injections of radiolabeled murine monoclonal antibodies. Cancer Biother 1994; 9: 17–28.

    Article  PubMed  CAS  Google Scholar 

  57. Dillman RO. Antibodies as cytotoxic therapy. J Clin Oncol 1994; 12: 1497–1515.

    PubMed  CAS  Google Scholar 

  58. Dillman RO, Beauregard JC, Jamieson M, et al. Toxicities associated with monoclonal antibody infusions in cancer patients. Molec Biother 1988; 1: 81–85.

    CAS  Google Scholar 

  59. Dillman RO. Monoclonal antibodies for treating cancer. Ann Intern Med 1989; 111: 592–603.

    PubMed  CAS  Google Scholar 

  60. Dorfman NA. The optimal technological approach to the development of human hybridomas. J Biol Response Modif 1985; 4: 213–239.

    CAS  Google Scholar 

  61. Dyer MJS, Hale G, Hayhoe FGJ, et al. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: Influence of antibody isotype. Blood 1989; 73: 1431–1439.

    PubMed  CAS  Google Scholar 

  62. Edelson RL, Raafat J, Berger CL, Grossman M, Troyer C, Hardy M. Anti-thymocyte globulin in the management of cutaneous T-cell lymphoma. Cancer Treat Rep 1979; 63 : 675–680.

    PubMed  CAS  Google Scholar 

  63. Editorial. Lancet 1994; 344: 1013.

    Google Scholar 

  64. Ehrlich P. Uben den jetzigen stand der Karzinomforschung. In: The collected papers of Paul Ehrlich. Vol. II. London: Pergamon Press 1957: 550–557.

    Google Scholar 

  65. Eisenberg BI. The polymerase chain reaction. N Engl J Med 1990; 322: 178–183.

    Article  Google Scholar 

  66. Elias DJ, Hirschowitz L, Kline LE, et al. Phase I clinical comparative study of monoclonal antibody KS1/4 and KSl/4-methotrexate immunoconjugate in patients with non-small cell lung carcinoma. Cancer Res 1990; 50: 4154–4159.

    PubMed  CAS  Google Scholar 

  67. Epenetos AA, Shepherd J, Britton KE, et al. 123-1 radioiodinated antibody imaging of occult ovarian cancer. Cancer 1985; 55: 984–987.

    Article  PubMed  CAS  Google Scholar 

  68. Fiddler I J, Hart IR. Biological diversity in metastatic neoplasms: origins and implications. Science 1982; 217: 998–1003.

    Article  Google Scholar 

  69. Fisher RI, Kobota TT, Mandell GL, et al. Regression of a T-cell lymphoma after administration of anti-thymocyte globulin. Ann Intern Med 1978; 88: 799–800.

    PubMed  CAS  Google Scholar 

  70. Foon KA, Bernhard MI, Oldham RK. Monoclonal antibody therapy: assessment by animal tumor models. J Biol Resp Modif 1982; 1:277–304.

    Google Scholar 

  71. Foon KA, Bunn PA, Schroff RW, et al. Monoclonal antibody therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma: preliminary observations. In: Langman RE, Trowbridge IS, Dulbecco R, eds. Monoclonal antibody and Cancer. New York: Academic Press 1984; pp39–52.

    Google Scholar 

  72. Foon KA, Schroff RW, Bunn PA, et al. Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia. Blood 1984; 64: 1085–1093.

    PubMed  CAS  Google Scholar 

  73. Frank MM. Complement in the pathophysiology of human disease. N Engl J Med 1987; 316: 1525–1530.

    Article  PubMed  CAS  Google Scholar 

  74. Frodin JE, Harmenberg U, Biberfeld P, et al. Clinical effects of monoclonal antibodies [MAb 17-1 A] in patients with metastatic colorectal carcinomas. Hybridoma 1988; 7:309–321.

    Article  PubMed  CAS  Google Scholar 

  75. Furukawa K, Yamaguchi H, Oettgen HF, et al. Two human monoclonal antibodies reacting with the major gangliosides of human melanomas and comparison with corresponding mouse monoclonal antibodies. Cancer Res 1989; 49: 191–196.

    PubMed  CAS  Google Scholar 

  76. Geha RS. Idiotypic-anti-idiotypic interactions in humans. J Biol Response Modif 1984; 3: 573–579.

    CAS  Google Scholar 

  77. Geha RS. Regulation of the immune response by idiotypeanti- idiotype interactions. N Engl J Med 1981; 305: 25–28.

    Article  PubMed  CAS  Google Scholar 

  78. Glassy MC, Dillman RO. Molecular biotherapy with human monoclonal antibodies. Molec Biother 1988; 1: 7–13.

    CAS  Google Scholar 

  79. Glassy MC, Handley HH, Hagiwara H, et al. UC729-6, a human lymphoblastoid B-cell line useful for generating antibody-secreting human-human hybridomas. Proc Natl Acad Sci 1983; 80: 6327–6331.

    Article  PubMed  CAS  Google Scholar 

  80. Glassy MC. Immortalization of human lymphocytes from a tumor-involved lymph node. Cancer Res 1987; 47: 5181–5188.

    PubMed  CAS  Google Scholar 

  81. Goodman GE, Hellstrom I, Brodzinsky L, et al. Phase I trial of murine monoclonal antibody L6 in breast, colon, ovarian, and lung cancer. J Clin Oncol 1990; 8:1083–1092.

    PubMed  CAS  Google Scholar 

  82. Goodman GL, Beaumier P, Hellstrom I, et al. Pilot trial of murine monoclonal antibodies in patients with advanced melanoma. J Clin Oncol 1985; 3: 340–352.

    PubMed  CAS  Google Scholar 

  83. Goustin AS, Leof EB, Shipley GD, et al. Growth factors and cancer. Cancer Res 1986; 46: 1015–1029.

    PubMed  CAS  Google Scholar 

  84. Greene WC, Leonard WJ, Depper JM, et al. The human interleukin-2 receptor: Normal and abnormal expression in T cells and in leukemias induced by the human T lymphotropic retroviruses. Ann Intern Med 1986; 105: 560–572.

    PubMed  CAS  Google Scholar 

  85. Greiner JW, Hand PH, Nugochi P, et al. Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte alpha-interferon treatment. Cancer Res 1984; 44: 3208–3214.

    PubMed  CAS  Google Scholar 

  86. Greiner JW, Guadagni F, Goldstein D, et al. Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells .J Clin Oncol 1992; 10: 735–746.

    PubMed  CAS  Google Scholar 

  87. Haisma HJ, Pinedo HM, Kessel MAP, et al. Human IgM monoclonal antibody 16.88: Pharmacokinetics and immunogenicity in colorectal cancer patients. J Natl Cancer Inst 1991; 83: 1813–1819.

    Article  PubMed  CAS  Google Scholar 

  88. Hale G, Dyer M, Clark MR, et al. Remission induction in non-Hodgkins lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 1988; 2: 1394–1399.

    Article  PubMed  CAS  Google Scholar 

  89. Halpern SE, Dillman RO, Witztum KF, et al. Radioimmunodetection of melanoma utilizing lll-In-96.5 monoclonal antibody: a preliminary report. Radiology 1985;155:493–499.

    PubMed  CAS  Google Scholar 

  90. Halpern SE, Dillman RO. Radioimmunodetection with monoclonal antibodies against prostatic acid phosphatase. In: Nuclear Medicine in Clinical Oncology. Winkler C, ed. Springer Verlag, Berlin, Heidelberg 1986; pp 164–170.

    Google Scholar 

  91. Halpern SE, Haindl W, Beauregard J, et al. Scintigraphy with In-Ill-labeled monoclonal antitumor antibodies: Kinetics, biodistribution, and tumor detection. Radiology 1988; 168:529–536.

    PubMed  CAS  Google Scholar 

  92. Hamblin TJ, Abdul-Ahad AK, Gordon J, et al. Preliminary experience in treating lymphocytic leukemia with antibody to immunoglobulin idiotypes on the cell surfaces. Br J Cancer 1980; 42: 495–502.

    Article  PubMed  CAS  Google Scholar 

  93. Hamblin TJ, Cattan AR, Glennie MJ, et al. Initial experience in treating human lymphoma with a chimeric univalent derivative of monoclonal anti-idiotype antibody. Blood 1987; 69: 790–797.

    PubMed  CAS  Google Scholar 

  94. Haspel MV, McCabe RP, Pomato N, et al. Generation of tumor cell-reactive human monoclonal antibodies using peripheral blood lymphocytes from actively immunized colorectal carcinoma patients. Cancer Res 1985; 45: 3951–3961.

    PubMed  CAS  Google Scholar 

  95. Haughton G, Lanier LL, Babcock GF, et al. Antigeninduced murine B cell lymphomas. II. Exploitation of the surface idiotype as tumour specific antigen. J Immunol 1978;121:2358–2362.

    PubMed  CAS  Google Scholar 

  96. Hekman A, Honselaar A, Vuist WM, et al. Initial experience with treatment of human B cell lymphoma with anti-CD 19 monoclonal antibody. Cancer Immunol Immunother 1991; 32: 364–372.

    Article  PubMed  CAS  Google Scholar 

  97. Hellstrom I, Garrigues U, Lavie E, et al. Antibodymediated killing of human tumor cells by attached effector cells. Cancer Res 1988; 48: 624–627.

    PubMed  CAS  Google Scholar 

  98. Henney CS, Gillis S. Cell-mediated cytotoxicity. In: Paul WE, ed., Fundamental Immunology, pp New York, Raven Press, 1984, pp669–684.

    Google Scholar 

  99. Heppner GH, Miller BE. Therapeutic implications of tumor heterogeneity. Semin Oncol 1989; 16: 91–105.

    PubMed  CAS  Google Scholar 

  100. Herberman RB, Orew ME, Rogentine GN, et al. Cytolytic effects of alloantiserum in patients with lymphoproliferative disorders. Cancer 1971; 28: 365–371.

    Article  PubMed  CAS  Google Scholar 

  101. Heberman RB, Morgan AC, Reisfeld R, et al. Antibodydependent cellular cytotoxicity (ADCC) against human melanoma by human effector cells in cooperation with mouse monoclonal antibodies. In: Monoclonal Antibodies and Cancer Therapy. Reisfeld RA and Sell S, eds. A.R. Liss, Inc., New York. 1985; 27: 193–203.

    Google Scholar 

  102. Herlyn DM, Steplewski Z, Herlyn MF, et al. Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody. Cancer Res 1980; 40: 717–721.

    PubMed  CAS  Google Scholar 

  103. Herlyn D, Koprowski H. IgG2A monoclonal antibodies inhibit human tumor growth through interaction with effector cells. Proc Natl Acad Sci USA 1982; 79: 4761–4765.

    Article  PubMed  CAS  Google Scholar 

  104. Herlyn D, Ross A, Koprowski H. Anti-idiotypic antibodies bear the internal image of a human tumor antigen. Science 1986; 232: 100–102.

    Article  PubMed  CAS  Google Scholar 

  105. Herlyn D, Wettendorff M, Schmoll E, et al. Anti-idiotype immunization of cancer patients: Modulation of the immune response. Proc Natl Acad Sch USA 1987; 84: 8055–8059.

    Article  CAS  Google Scholar 

  106. Hersey P, Schibeci SD, Townsend P, et al. Potentiation of lymphocyte responses by monoclonal antibodies to the ganglioside GD3. Cancer Res 1986; 46: 6083–6090.

    PubMed  CAS  Google Scholar 

  107. Hornung SJ, Rosenberg SA. The natural history of initially untreated low grade non-Hodgkin’s lymphoma. N Engl J Med 1984; 311: 1471–1475.

    Article  Google Scholar 

  108. Houghton AN, Mintzer D, Cordon-Cardo C, et al. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci USA 1985; 82: 1242–1246.

    Article  PubMed  CAS  Google Scholar 

  109. Hu F, Epstein AL, Naeve GS, et al. A phase la clinical trial of LYM-1 monoclonal antibody serotherapy in patients with refractory B cell malignancies. Hematol Oncol 1989; 7:155–166.

    Article  PubMed  CAS  Google Scholar 

  110. Iliopoulos D, Ernst C, Steplewski Z, et al. Inhibition of metastases of a human melanoma xenograft by monoclonal antibody to the GD2/GD3 gangliosides. J Natl Cancer Inst 1989; 81:440–444.

    Article  PubMed  CAS  Google Scholar 

  111. Imai K, Pellegrino MA, Wilson BS, et al. Higher cytolytic efficiency of an IgG2A than of an IgGl monoclonal antibody with the same (or spatially close) determinant on a human molecular-weight melanoma-associated antigen. Cell Immunol 1982; 72: 239–247.

    Article  PubMed  CAS  Google Scholar 

  112. Irie RF, Sze LL, Saxton RE. Human antibody to OFA-1, a tumor antigen produced in vitro by Epstein-Barr virus transformed human B-lymphoid cell lines. Proc Natl Acad Sci USA 1982; 79: 5666–5670.

    Article  PubMed  CAS  Google Scholar 

  113. Irie RF, Matuski T, Morton DL. Human monoclonal antibody to ganglioside GM2 for melanoma treatment [letter]. Lancet 1989; 1:786–787.

    Article  PubMed  CAS  Google Scholar 

  114. Janson D, Hoffman M, Fuchs A, et al. Campath 1-H therapy causes clearing of lymphocytic infiltration of bone marrow in advanced refractory chronic lymphocytic leukemia. Blood 84() 1994; 526a.

    Google Scholar 

  115. Jerne NK. Towards a network theory of the immune system. Ann Immunol 1974; 125C: 373.

    CAS  Google Scholar 

  116. Johnson JP, Riethmuller G. Monoclonal antibodies and melanomas. In: Handbook of Monoclonal Antibodies, Applications in Biology and Medicine. Ferrone S and Dierich MP, eds. Noyes pub., Parkridge NJ, 1985; pp347–359.

    Google Scholar 

  117. Junghans RP, Waldmann TA, Landolfi NF, et al. Anti-tac- H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res 1990; 50: 1495–1502.

    PubMed  CAS  Google Scholar 

  118. Kaliss N. Immunological enhancement of tumor homografts in mice: a review. Cancer Res 1958; 18: 992–994.

    PubMed  CAS  Google Scholar 

  119. Kan-Mitchell J, Iman A, Kempf RA, et al. Human monoclonal antibodies directed against melanoma tumorassociated antigens. Cancer Res 1986; 46:2490–2496.

    PubMed  CAS  Google Scholar 

  120. Kelley MJ, Avis I, Linnoila RI, et al. Complete response in a patient with small cell lung cancer treated on a phase II trial using a murine monoclonal antibody (2A11) directed against gastrin-releasing peptide. Proc Am Soc Clin Oncol 1993; 12: 339.

    Google Scholar 

  121. Kennedy RC, Eichberg JW, Lanford RE, Dreesman GR. Anti-idiotypic antibody vaccine for type B viral hepatitis in chimpanzees. Science 1986; 232: 220–223.

    Article  PubMed  CAS  Google Scholar 

  122. Kennedy RC, Zhou EM, Lanford RE, et al. Possible role of anti-idiotypic antibodies in the induction of tumor immunity. J Clin Invest 1987; 80: 1217–1224.

    Article  PubMed  CAS  Google Scholar 

  123. Khazaeli MB, Saleh MN, Liu TP, et al. Pharmacokinetics and immune response of 131I-chimeric mouse/human B72.3 (human γ) monoclonal antibody in humans. Cancer Res 1991; 51: 5461–5466.

    PubMed  CAS  Google Scholar 

  124. Khazaeli MB, Conry RM, LoBuglio AF. Human immune response to monoclonal antibodies. J Immunother 1994; 15:42–52.

    Article  CAS  Google Scholar 

  125. Kirkwood JM, Neumann RD, Zoghbi SS, et al. Scintigraphic detection of metastatic melanoma using Indium- 111/DTPA conjugated anti-gp240 antibody [ZME018]. J Clin Oncol 1987; 5: 1247–1255.

    PubMed  CAS  Google Scholar 

  126. Kirch ME, Hammerling U. Immunotherapy of murine leukemias by monoclonal antibody: effect of passively administered antibody on growth of transplanted tumor cells. J Immunol 1981; 127: 805–810.

    PubMed  CAS  Google Scholar 

  127. Kjeldson TB, Rasmussen BB, Rose C, Zeuthen J. Humanhuman hybridomas and human monoclonal antibodies obtained by fusion of lymph node lymphocytes from breast cancer patients. Cancer Res 1988; 48: 3208–3214.

    Google Scholar 

  128. Koprowski H, Herlyn D, Lubeck M, et al. Human antiidiotype antibodies in cancer patients: is the modulation of the immune response beneficial for the patient? Proc Natl Acad Sci USA 1984; 81:216–219.

    Article  PubMed  CAS  Google Scholar 

  129. Klein B, Wijdenes J, Zhang XG, et al. Murine anti-interleukin 6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 1991; 78: 1198–1204.

    PubMed  CAS  Google Scholar 

  130. Kolitz JE, O’Mara KY Willemze R, et al. Treatment of acute lymphoblastic leukemia with CAMPATH-1H: initial observations. Blood 1994; 84 (suppl 1) 301a.

    Google Scholar 

  131. Knox SJ, Levy R, Hodgkinson S, et al. Observations on the effect of chimeric anti-CD4 monoclonal antibody in patients with mycosis fungoides. Blood 1991; 77: 20–30.

    PubMed  CAS  Google Scholar 

  132. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predetermined specificity. Nature 1975;256:495–597.

    Article  PubMed  CAS  Google Scholar 

  133. Koprowski H, Steplewski Z, Herlyn D, et al. Study of antibodies against human melanoma produced by somatic cell hybrids. Proc Natl Acad Sci USA 1978; 75: 3405–3409.

    Article  PubMed  CAS  Google Scholar 

  134. Kosmos C, Epenetos AE, Colurtenay-Luck NS. Activation of cellular immunity after intracavitary monoclonal antibody therapy of ovarian cancer. Cancer 1994; 73:3000–3010.

    Article  Google Scholar 

  135. Larrick JW, Bourla JM. Prospects for therapeutic use of human monoclonal antibodies. J Biol Response Mod 1986;5:379–393.

    PubMed  CAS  Google Scholar 

  136. Larson SM, Brown, JP, Wright PW, et al. Imaging of melanoma with 1-131-labeled monoclonal antibodies. J Nucl Med 1982; 24: 123–129.

    Google Scholar 

  137. Lanier LL, Babcock GF, Raybourne RB, et al. Mechanism of B cell lymphoma immunotherapy with passive xenogeneic anti-idiotype serum. J Immunol 1980; 125: 1730–1736.

    PubMed  CAS  Google Scholar 

  138. Laszlo J, Buckley CE, Amos DB. Infusion of isologous immune plasma in chronic lymphocytic leukemia. Blood 1968; 31: 104–110.

    PubMed  CAS  Google Scholar 

  139. Leder P. The genetics of antibody diversity. Sci Amer 1980;243:102–115.

    Article  Google Scholar 

  140. Leroy M. Teillac P, Rain JD, et al. Radioimmunodetection of lymph node invasion in prostatic cancer. Cancer 1989; 64:1–5.

    Article  PubMed  CAS  Google Scholar 

  141. Letvin NL, Ritz J, Guida LJ, et al. In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates: I. effects of anti-Til antibodies on the circulating T cell pool. Blood 1985; 66: 961–966.

    PubMed  CAS  Google Scholar 

  142. Levy R, Miller RA. Biological and clinical indications of lymphocyte hybridomas: tumor therapy with monoclonal antibodies. Ann Rev Med 1983; 34: 107–116.

    Article  PubMed  CAS  Google Scholar 

  143. Levy R. Will monoclonal antibodies find a place in our therapeutic armamentarium? J Clin Oncol 1987; 5: 527–529.

    PubMed  CAS  Google Scholar 

  144. Liao S, Kwong PC, Khosravi M, Dent PB. Enhanced expression of melanoma-associated antigens and B2- microglobulin on cultured human melanoma cells by interferon.J Natl Cancer Inst 1982; 68: 19–25.

    PubMed  CAS  Google Scholar 

  145. Liao SK, Meranda C, Avner BP, et al. Immunohistochemical phenotyping of human solid tumors with monoclonal antibodies in devising biotherapeutic strategies. Cancer Immunol Immunother 1989; 28: 77–86.

    Article  PubMed  CAS  Google Scholar 

  146. Lindstrom BA. An experimental study of myelotoxic sera. Therapeutic attempts in myeloid leukaemia. Acta Med Scand Suppl 1927; 22: 1–169.

    Google Scholar 

  147. Liu AY, Robinson RR, Hellstrom AE, et al. Chimericmouse-human IgGl antibody that can mediate lysis of cancer cells. Proc Natl Acad Sci USA 1987; 84: 3439–3443.

    Article  PubMed  CAS  Google Scholar 

  148. LoBuglio AF, Saleh MN, Lee J, et al. Phase I trial of multiple large doses of murine monoclonal antibody C017-1A.I Clinic aspects. J Natl Cancer Inst 1988; 17: 932–936.

    Google Scholar 

  149. LoBuglio AF, Wheeler RH, Trang J, et al. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci USA 1989; 86: 4220–4224.

    Article  PubMed  CAS  Google Scholar 

  150. Lowder JN, Meeker TC, Campbell M, et al. Studies on B lymphoid tumors treated with monoclonal anti-idiotype antibodies: Correlation with clinical responses. Blood 1987; 69: 199–210.

    PubMed  CAS  Google Scholar 

  151. Lubeck MD, Steplewski Z, Baglia F, et al. The interaction of murine IgG subclass proteins with human monocyte Fc receptors. J Immunol 1985; 135: 1299–1304.

    PubMed  CAS  Google Scholar 

  152. Mach J-P, Chatal J-F, Lumbroso J-D, et al. Tumor localization in patients by radiolabeled monoclonal antibodies against colon carcinoma. Cancer Res 1983; 43: 5593–5600.

    PubMed  CAS  Google Scholar 

  153. Maguire RT, VanNostrand D. Diagnosis of colorectal and ovarian carcinoma. New York: Marcel Dekker Inc, 1992.

    Google Scholar 

  154. Maloney DG, Levy R, Miller RA. Monoclonal antiidiotype therapy of Ball lymphoma. Biological Therapy of Cancer Updates 1992; 6: 1–10.

    Google Scholar 

  155. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single dose infusion of chimeric monoclonal antibody (IDEC C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84: 2457–2466.

    PubMed  CAS  Google Scholar 

  156. Maloney DG, Bodkin D, Grillo-Lopez AJ, et al. IDECC2B8: final report on a phase II trial in relapsed non- Hodgkin’s lymphoma. Blood 1994; 84(suppl 1): 169a.

    Google Scholar 

  157. Masui H, Kawamoto T, Sato JD, et al. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1984; 44: 1002–1007.

    PubMed  CAS  Google Scholar 

  158. Meeker TC, Lowder J, Maloney DG, et al. A clinical trial of anti-idiotype therapy for B cell malignancy. Blood 1985;65:1349–1372.

    PubMed  CAS  Google Scholar 

  159. Meeker T, Lowder J, Cleary ML, et al. Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. Blood 1985; 65: 1373–1381.

    Google Scholar 

  160. Mellstedt H, Frodin J-E, Masucci G, et al. The therapeutic use of monoclonal antibodies in colorectal carcinoma. Semin Oncol 1991; 18:462–477.

    PubMed  CAS  Google Scholar 

  161. Metzger H, Kinnet JP. How antibodies work: focus on Fc receptors. FASEB J 1988; 2: 311.

    Google Scholar 

  162. Miller RA, Maloney DG, Warnke R, et al. Treatment of Bcell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 1981; 306: 517–522.

    Article  Google Scholar 

  163. Miller RA, Levy R. Response of cutaneous T cell lymphoma to therapy with hybridoma monoclonal antibody. Lancet 1981; 2: 226–230.

    Article  PubMed  CAS  Google Scholar 

  164. Miller RA, Maloney DG, McKillop J, Levy R. In vivo effects of murine hybridoma monoclonal antibody in a patient with T-cell leukemia. Blood 1981; 58: 78–86.

    PubMed  CAS  Google Scholar 

  165. Miller RA, Oseroff AR, Stratte PT, et al. Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood 1983; 62: 988–995.

    PubMed  CAS  Google Scholar 

  166. Miller RA, Hart S, Samoszuk M, et al. Shared idiotypes expressed by human B-cell lymphomas. N Engl J Med 1989;321:851–857.

    Article  PubMed  CAS  Google Scholar 

  167. Minasian LM, Szatrowski TP, Rosenblum M, et al. Hemorrhagic tumor necrosis during a pilot trial of tumor necrosis factor-a and anti-GD3 ganglioside monoclonal antibody in patients with metastatic melanoma. Blood 1994; 83:56–64.

    PubMed  CAS  Google Scholar 

  168. Minasian ML, Yao TJ, Steffens TA, et al. A phase I study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-colony stimulating factor inpatients with metastatic melanoma. Cancer 1995; 75:2251–2257.

    Article  PubMed  CAS  Google Scholar 

  169. Mittelman A, Chen ZJ, Kageshita T, et al. Active specific immunotherapy in patients with melanoma: A clinical trial with mouse antiidiotypic monoclonal antibodies elicited with synergeneic anti-high-molecular-weight melanoma-associated antigen monoclonal antibodies. J Clin Invest 1990; 86: 2136–2144.

    Article  PubMed  CAS  Google Scholar 

  170. Mittelman A, Chen ZJ, Yang H, et al. Human high molecular weight melanoma-associated antigen (HMWMAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: Induction of humoral anti-HMWMAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci USA 1992; 89:466–470.

    Article  PubMed  CAS  Google Scholar 

  171. Molodofsky PJ, Sears HF, Mulhearn Jr CB, et al. Detection of metastatic tumor in normal sized retroperitoneal lymph nodes by monoclonal antibody imaging. N Engl J Med 1984; 311: 106–107.

    Article  Google Scholar 

  172. Morrison SL, Oi T. Genetically engineered antibody molecules. Adv Immunol 1989; 44: 65–92.

    Article  PubMed  CAS  Google Scholar 

  173. Mujoo K, Kipps TJ, Yang HM, et al. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. Cancer Res 1989; 49:2857–2861.

    PubMed  CAS  Google Scholar 

  174. Mulshine JL, Avis I, Treston AM, et al. Clinical use of a monoclonal antibody to bombesin-like peptide in patients with lung cancer .Ann NY Acad Sci 1988; 547: 360–372.

    Article  PubMed  CAS  Google Scholar 

  175. Munn DH, Cheung N-KV Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma. Cancer Res 1987; 47: 6600–6605.

    PubMed  CAS  Google Scholar 

  176. Murray JL, Rosenblum MG, Sobol RE, et al. Radioimmunoimaging in malignant melanoma with 111 -Inlabeled monoclonal antibody 96.5. Cancer Res 1985; 45: 2376–2381.

    Google Scholar 

  177. Murray JL, Rosenblum MG, Lamki K, et al. Clinical parameters related to optimal tumor localization of Indium- 111-labeled mouse antimelanoma monoclonal antibody ZME018. J Nucl Med 1987; 28:25–33.

    PubMed  CAS  Google Scholar 

  178. Murray JL, Cunningham JE, Brewer H, et al. Phase I trial of murine monoclonal antibody 14G21 administered by prolonged intravenous infusion in patients with neuroectodermal tumor. J Clin Oncol 1994; 12: 184–193.

    PubMed  CAS  Google Scholar 

  179. Nadler LM, Stashenko P, Hardy R, et al. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 1980; 40:3147–3154.

    PubMed  CAS  Google Scholar 

  180. Nicholson GL. Tumor cell instability, diversification, and progression to the metastatic phenotype: From oncogene to oncofetal expression. Cancer Res 1987; 47: 1473–1487.

    Google Scholar 

  181. Nisonoff A. Idiotypes: Concepts and applications. J Immunol 1991; 147: 2429–2438.

    PubMed  CAS  Google Scholar 

  182. Oldham RK. Monoclonal antibodies in cancer therapy. J Clin Oncol 1983; 1: 582–590.

    PubMed  CAS  Google Scholar 

  183. Oldham RK, Foon KA, Morgan C, et al. Monoclonal antibody therapy of malignant melanoma: In vivo localization in cutaneous metastases after intravenous administration. J Clin Oncol 1984; 2: 1235–1244.

    PubMed  CAS  Google Scholar 

  184. Oldham RK. Monoclonal antibodies: does sufficient selectivity to cancer cells exist for therapeutic application? J Biol Response Med 1987; 6:227–234.

    CAS  Google Scholar 

  185. Oosterwijk E, Debruyne FMJ, Schalken JA. The use of monoclonal antibody G250 in the therapy of renal-cell carcinoma. Semin Oncol 1995; 22: 34–41.

    PubMed  CAS  Google Scholar 

  186. Pegram M, Lipton A, Pietras R, et al. Phase II study of intravenous recombinant humanized anti-pl85 Her-2 monoclonal antibody plus cisplatin in patients with Her-2 neu overexpressing metastatic breast cancer. Proc Am Soc Clin Oncol 1995; 14: 106.

    Google Scholar 

  187. Perek Y, Hurwitz E, Burowski D, Haimovich J. Immunotherapy of a murine B-cell tumor with antibodies and F(ab’)2 fragments against idiotypic determinants of its cell surface IgM. J Immunol 1983; 131: 1600–1603.

    PubMed  CAS  Google Scholar 

  188. Press OW, Appelbaum F, Ledbetter JA, et al. Monoclonal antibody 1F5 [anti-CD-20] serotherapy of human B cell lymphomas. Blood 1987; 69: 584–591.

    PubMed  CAS  Google Scholar 

  189. Pukel CS, Lloyd KO, Travassos LR, et al. GD3, a prominent ganglioside of human melanoma. J Exp Med 1982; 155:1133–1147.

    Article  PubMed  CAS  Google Scholar 

  190. Rankin EM, Hekman A, Somers R, et al. Treatment of two patients with B cell lymphoma with monoclonal antiidiotype antibodies. Blood 1985; 65: 1373–1381.

    PubMed  CAS  Google Scholar 

  191. Rietmuller G, Schneider-Gadicke E, Schlimok G, et al. Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes C colorectal carcinoma. Lancet 1994;343:1177–1183.

    Article  Google Scholar 

  192. Richards JM, Vogelzang NJ, Bluestone J.A. Neurotoxicity after treatment with muromonab-CD3. New Engl J Med 1990; 323:487–488.

    Article  PubMed  CAS  Google Scholar 

  193. Ritz J, Pesando JM, Notis-McConarty J, et al. Modulation of human acute lymphoblastic leukemia antigen induced by monoclonal antibody in vitro. J Immunol 1908; 125: 1506–1514.

    Google Scholar 

  194. Ritz J, Pesando JM, Sallan SE, et al. Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. Blood 1981;58:141–152.

    PubMed  CAS  Google Scholar 

  195. Rosenberg SA, Terry WD. Passive immunotherapy of cancer in animals and man. Adv Cancer Res 1977; 25: 323–388.

    Article  PubMed  CAS  Google Scholar 

  196. Rudders RA, Levin A, Jespersen D, et al. Crossreacting human lymphoma idiotypes. Blood 1992; 80: 1039–1044.

    PubMed  CAS  Google Scholar 

  197. Ryan KP, Dillman RO, DeNardo SJ, et al. Breast cancer imaging with In- 111 human IgM monoclonal antibodies. Radiol 1988; 167: 71–75.

    CAS  Google Scholar 

  198. Saleh MN, LoBuglio AF, Wheeler RH, et al. A phase II trial of murine monoclonal antibody 17-1A and interferon- gamma: Clinical and immunological data. Cancer Immunol 1990; 32: 185–190.

    Article  CAS  Google Scholar 

  199. Saleh MN, Khazaeli MB, Wheeler RH, et al. Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma. Cancer Res 1992; 52: 4342–4347.

    PubMed  CAS  Google Scholar 

  200. Saleh MN, Khazaeli MD, Wheeler RH, et al. Phase I trial of the chimeric anti-GD2 monoclonal antibody ch 14.18 in patients with malignant melanoma. Hum Antibod Hybridomas 1992: 3: 19–23.

    CAS  Google Scholar 

  201. Schecter AL, Stern DF, Vaidanathan L, et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumor antigen. Nature 1984; 312: 513–516.

    Article  Google Scholar 

  202. Scheinberg DA, Strand M. Leukemic cell targeting and therapy by monoclonal antibody in a mouse model system. Cancer Res 1982; 42:44–49.

    PubMed  CAS  Google Scholar 

  203. Scheinberg DA, Lovett D, Divgi CR, et al. A Phase I trial of monoclonal antibody Ml95 in acute myelogenous leukemia: Specific bone marrow targeting and internalization of radionuclide. J Clin One 1991; 9:478–490.

    CAS  Google Scholar 

  204. Schlom J, Wunderlich D, Teramoto YA. Generation of human monoclonal antibodies reactive with human mammary carcinoma cells. Proc Natl Acad Sci 1980; 77: 6841–6845.

    Article  PubMed  CAS  Google Scholar 

  205. Schnipper LE. Clinical implications of tumor cell heterogeneity. N Engl J Med 1986; 314: 1423–1431.

    Article  PubMed  CAS  Google Scholar 

  206. Schoof DD, Selleck CM, Massaro AF, et al. Activation of human tumor-infiltrating lymphocytes by monoclonal antibodies directed to the CD3 complex. Cancer Res 1990; 50: 1138–1143.

    PubMed  CAS  Google Scholar 

  207. Schroff RW, Farrell MM, Klein RA, et al. T65 antigen modulation in a phase I monoclonal antibody trial with chronic lymphocytic leukemia patients. J Immunol 1984; 133: 1641–1648.

    PubMed  CAS  Google Scholar 

  208. Schroff RW, Foon KA, Wilburn SB, et al. Human antimurine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res 1985; 45: 879–885.

    PubMed  CAS  Google Scholar 

  209. Sears HF, Atkinson B, Mattis J, et al. Phase I clinical trial of monoclonal antibody in treatment of gastrointestinal tumors. Lancet 1982; 1: 762–765.

    Article  PubMed  CAS  Google Scholar 

  210. Sears HF, Herlyn D, Steplewski Z, et al. Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma. J Biol Response Modif 1984; 3: 136–150.

    Google Scholar 

  211. Sears HF, Herlyn D, Steplewski Z, et al. Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma. Cancer Res 1985; 45: 5910–5913.

    PubMed  CAS  Google Scholar 

  212. Shakib F, ed. Basic and clinical aspects of IgG subclasses. New York: Carger, 1986.

    Google Scholar 

  213. Shaw DR, Khazaeli MB, LoBuglio AF. Mouse/human chimeric antibodies to a tumor-associated antigen: biologic activity of the four human IgG subclasses. J Natl Cancer Inst 1988; 80: 1553–1559.

    Article  PubMed  CAS  Google Scholar 

  214. Shawler DL, Miceli MC, Wormsley SB, et al. Induction of in vitro and in vivo antigenic modulation by the antihuman T cell monoclonal antibody T101. Cancer Res 1984; 44: 5921–5927.

    PubMed  CAS  Google Scholar 

  215. Shawler DL, Bartholomew RM, Smith LM, et al. Human immune response to multiple injections of murine monoclonal IgG. J Immunol 1985; 135: 1530–1535.

    PubMed  CAS  Google Scholar 

  216. Shawler DL, Wormsley SB, Dillman RO, et al. The use of monoclonal antibodies and flow cytometry to detect peripheral blood and bone marrow involvement of a diffuse, poorly differentiated lymphoma. Int J Immunopharmacol 1985; 7:423–432.

    Article  PubMed  CAS  Google Scholar 

  217. Shawler DL, McCallister TJ, Sobol RE, et al. Serologic and cellular assays to monitor therapy with murine monoclonal antibodies. J Clin Lab Anal 1987; 2:184–190.

    Article  Google Scholar 

  218. Shen JW, Atkinson B, Koprowsky H, et al. Binding of murine immunoglobulin to human tissues after immunotherapy with anti-colorectal carcinoma monoclonal antibody. Int J Cancer 1984; 33:465–468.

    Article  PubMed  CAS  Google Scholar 

  219. Sikora K, Wright R. Human monoclonal antibodies to lung cancer antigens. Br J Cancer 1981; 43: 696–700.

    Article  PubMed  CAS  Google Scholar 

  220. Sikora K, Alderson T, Phillips J, et al. Human hybridomas from malignant gliomas. Lancet 1982; 1: 11–14.

    Article  PubMed  CAS  Google Scholar 

  221. Sikora K, Alderson T, Ellis J, et al. Human hybridomas from patients with malignant disease. Br J Cancer 1983; 47: 135–145.

    Article  PubMed  CAS  Google Scholar 

  222. Sikora K. Human monoclonal antibodies. Brit Med Bull 1984; 40:209–212.

    PubMed  CAS  Google Scholar 

  223. Sikorska HM. Therapeutic applications of antiidiotype antibodies. J Biol Respons Modif 1987; 7: 327–358.

    Google Scholar 

  224. Sobol RE, Dillman RO, Smith JD, et al. Phase I evaluation of murine monoclonal anti-melanoma antibody in man: preliminary observations. In: Hybridomas in Cancer Diagnosis and Treatment. Mitchell MS, Oettgen HF, eds. New York: Raven Press, 1981; 21: 199–206.

    Google Scholar 

  225. Sosman JA, Weiss GR, Margolin KA, et al. Phase IB clinical trial of anti-CD3 followed by high dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma; clinical and immunologic effects. J Clin Oncol 1993; 11:1496–1505.

    PubMed  CAS  Google Scholar 

  226. Starling J, Cote RJ, Marder P, et al. Tissue distribution and cellular location of the antigens recognized by human monoclonal antibodies 16.88 and 28A32. Cancer Res 1988;48:7273–7278.

    PubMed  CAS  Google Scholar 

  227. Steplewski Z, Sun LK, Shearman CW, et al. Biological activity of human-mouse IgGl, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity. Proc Natl Acad Sci USA 1988; 85:4852–4856.

    Article  PubMed  CAS  Google Scholar 

  228. Stevenson FK, Bell AJ, Cusack R, et al. Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody. Blood 1991; 77: 1071–1079.

    PubMed  CAS  Google Scholar 

  229. Stratte PT, Miller RA, Amyx HL, et al. In vivo effects of murine monoclonal anti-human T cell antibodies in subhuman primates. J Biol Respons Modif 1982; 1:137–148.

    Google Scholar 

  230. Sumner WC, Foraker AG. Spontaneous regression of human melanoma: clinical and experimental studies. Cancer 1960; 13:79–81.

    Article  PubMed  CAS  Google Scholar 

  231. Tempero MA, Sivinski C, Steplewski Z, et al. Phase II trial of interferon gamma and monoclonal antibody 17-1A in pancreatic cancer: biologic and clinical effects. J Clin Oncol 1990; 8: 2019–2026.

    PubMed  CAS  Google Scholar 

  232. Thompson CH, Stacker SA, Salehi N, et al. Immunoscintigraphy for detection of lymph node metastases from breast cancer. 1984; 2: 1245–1247.

    Google Scholar 

  233. Thurin J, Thurin M, Kimoto Y, et al. Monoclonal antibody- defined correlations in melanoma between levels of GD2 and GD3 antigens and antibody-mediated cytotoxicity. Cancer Res 1987; 47: 1229–1233.

    PubMed  CAS  Google Scholar 

  234. Trowbridge IS, Domingo DL. Anti-transferrin receptor monoclonal antibody and toxin-antibody conjugates affect growth of human tumour cells. Nature 1981; 294: 171–173.

    Article  PubMed  CAS  Google Scholar 

  235. Urba WJ, Ewel C, Kopp W, et al. Anti-CD3 monoclonal antibody treatment of patients with CD3-negative tumors: Aphase IA/B study. Cancer Res 1992; 52: 2394–2401.

    PubMed  CAS  Google Scholar 

  236. Vadhan-Raj S, Cordon-Cardo C, Carswell E, et al. Phase I trial of mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites. J Clin Oncol 1988; 6: 1636–1648.

    PubMed  CAS  Google Scholar 

  237. Vitetta ES, Uhr JW. Monoclonal antibodies as agonists: an expanded role for their use in cancer therapy. Cancer Res 1994; 54: 5301–5309.

    PubMed  CAS  Google Scholar 

  238. Waldmann TA. The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science 1986; 232: 727–732.

    Article  PubMed  CAS  Google Scholar 

  239. Waldmann, TA, Goldman CK, Bongiovanni KF, et al. Therapy of patients with human T-cell lymphotropic virus I-induced adult T-cell leukemia with anti-tac, a monoclonal antibody to the receptor for interleukin-2. Blood 1988;72:1805–1816.

    PubMed  CAS  Google Scholar 

  240. Waldmann TA, Pastan IH, Gansow OA, et al. The multichain interleukin-2 receptor: A target for immunotherapy. Ann Intern Med 1992; 116: 148–160.

    PubMed  CAS  Google Scholar 

  241. Wallach D, Fellous M, Revel M. Preferential effect of gamma interferon on the synthesis of HLA antigens and their mRNAs in human cells. Nature 1982; 299: 833–835.

    Article  PubMed  CAS  Google Scholar 

  242. Weiner GJ, Hillstrom JR. Bispecific anti-idiotype/anti- CD3 antibody therapy of murine B cell lymphoma. J Immunol 1991; 147:4035–4044.

    PubMed  CAS  Google Scholar 

  243. Weiner LM, Moldofsky PH, Gatenby RA, et al. Antibody delivery and effector cell activation in a phase II trial of recombinant gamma-interferon and the murine monoclonal antibody CO 17-1A in advanced colorectal carcinoma. Cancer Res 1988; 48: 2568–2573.

    PubMed  CAS  Google Scholar 

  244. Weiner LM, Steplewski Z, Koprowski H, et al. Divergent dose-related effects of gamma-interferon therapy on in vitro antibody-dependent cellular and nonspecific cytotoxicity by human peripheral blood monocytes. Cancer Res 1988; 48:1042–1046.

    PubMed  CAS  Google Scholar 

  245. Weiner LM, Harvey E, Padavic-Shaller K, et al. Phase II multicenter evaluation of prolonged murine monoclonal antibody 17-1A therapy in pancreatic carcinoma. J Immunother 1993; 13: 110–116.

    Article  CAS  Google Scholar 

  246. Welte K, Miller G, Chapman PB, et al. Stimulation of T lymphocyte proliferation by monoclonal antibodies against GD3 ganglioside. J Immunol 1987; 139: 1763–1771.

    PubMed  CAS  Google Scholar 

  247. Wettendorff M, Hiopoulos D, Tempero M, et al. Idiotypic cascades in cancer patients treated with monoclonal antibody C017-1A. Proc Natl Acad Sci USA 1989; 86: 3787–3791.

    Article  PubMed  CAS  Google Scholar 

  248. Wilkinson I, Jackson C-JC, Lang GM, et al. Tolerance induction in mice by conjugates of monoclonal immunoglobulins and monomethoxypolyethylene glycol: transfer of tolerance by T cells and by T cell extracts. J Immunol 1987; 139: 326–331.

    PubMed  CAS  Google Scholar 

  249. Winter G, Milstein C. Man-made antibodies. Nature 1991;349:293–299.

    Article  PubMed  CAS  Google Scholar 

  250. Wiseman C, Hammock Y Barton L, et al. Clinical responses of primary human CNS tumors to OKT3/ cyclophosphamide. J Immunother 1994; 16: 245.

    Article  Google Scholar 

  251. Wong KK, Sweet DL, Variakoujis D. The treatment of lymphoblastic lymphoma with antithymocyte globulin. Cancer 1981; 50: 57–61.

    Article  Google Scholar 

  252. Wong JF, Colvin RB. Bi-specific monoclonal antibodies. Selective binding and complement fixation to cells that express two different surface antigens. J Immunol 1987; 139: 1369–1374.

    PubMed  CAS  Google Scholar 

  253. Woodhouse CS, Morgan AC Jr. Murine monoclonal IgG3 antibodies to human colorectal tumor-associated antigens: production and characterization of antibodies active in both antibody-dependent cellular cytotoxicity and complement-mediated cytolysis. Cancer Res 1989; 49:2766–2772.

    PubMed  CAS  Google Scholar 

  254. Wright PW, Hellstrom KE, Hellstrom IE, et al. Serotherapy of malignant disease. Med Clin North Am 1976; 60:607–622.

    PubMed  CAS  Google Scholar 

  255. Yoshikawa K, Ueda R, Obata Y, et al. Human monoclonal antibody reactive to stomach cancer produced by mousehuman hybridoma technique. Jpn J Cancer Res 1986; 77: 1122–1133.

    PubMed  CAS  Google Scholar 

  256. Young WW, Hakomori S. Therapy of mouse lymphoma with monoclonal antibodies to glycolipid: selection of low antigenic variance in vivo. Science 1981; 211:487–489.

    Article  PubMed  CAS  Google Scholar 

  257. Yu AL, Uttenreuther MM, Kamps A, et al. Combined use of human-mouse chimeric anti-GD2 (chl4.18) in the treatment of refractory neuroblastoma. Antibody Immunocon Radiopharm 1995; 8: 61.

    Google Scholar 

  258. Ziegler LD, Palazzolo, Cunningham J, et al. Phase I trial of murine monoclonal antibody L6 in combination with subcutaneous interleukin-2 in patients with advanced carcinoma of the breast, colorectum, and lung. J Clin Oncol 1992; 10: 1470–147

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hoag Cancer Center, Newport Beach, California, USA

    Robert O. Dillman

  2. University of California, Irvine, California, USA

    Robert O. Dillman

Authors
  1. Robert O. Dillman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Biological Therapy Institute Foundation, Franklin, Tennessee, USA

    Robert K. Oldham M.D. (Clinical Professor of Medicine) (Clinical Professor of Medicine)

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Dillman, R.O. (1998). Antibody Therapy. In: Oldham, R.K. (eds) Principles of Cancer Biotherapy. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-0029-5_12

Download citation

  • DOI: https://doi.org/10.1007/978-94-009-0029-5_12

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-6501-6

  • Online ISBN: 978-94-009-0029-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation